Mediolanum International Funds Ltd Buys 68,104 Shares of Boston Scientific Co. (NYSE:BSX)

Mediolanum International Funds Ltd increased its stake in shares of Boston Scientific Co. (NYSE:BSX) by 14.9% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 525,076 shares of the medical equipment provider’s stock after acquiring an additional 68,104 shares during the quarter. Mediolanum International Funds Ltd’s holdings in Boston Scientific were worth $46,973,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of BSX. Sunbelt Securities Inc. boosted its holdings in shares of Boston Scientific by 85.8% during the 2nd quarter. Sunbelt Securities Inc. now owns 1,213 shares of the medical equipment provider’s stock worth $93,000 after buying an additional 560 shares during the period. Quarry LP acquired a new stake in Boston Scientific in the 2nd quarter worth about $33,000. EP Wealth Advisors LLC raised its stake in Boston Scientific by 4.1% in the 2nd quarter. EP Wealth Advisors LLC now owns 13,066 shares of the medical equipment provider’s stock worth $1,006,000 after purchasing an additional 514 shares in the last quarter. Truist Financial Corp raised its stake in Boston Scientific by 1.1% in the 2nd quarter. Truist Financial Corp now owns 214,594 shares of the medical equipment provider’s stock worth $16,526,000 after purchasing an additional 2,254 shares in the last quarter. Finally, Cetera Investment Advisers raised its stake in Boston Scientific by 2.9% in the 2nd quarter. Cetera Investment Advisers now owns 295,984 shares of the medical equipment provider’s stock worth $22,794,000 after purchasing an additional 8,399 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Trading Up 0.2 %

BSX opened at $102.97 on Friday. Boston Scientific Co. has a fifty-two week low of $62.63 and a fifty-two week high of $104.25. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02. The firm has a market capitalization of $151.75 billion, a price-to-earnings ratio of 85.10, a PEG ratio of 2.63 and a beta of 0.80. The company’s 50 day moving average price is $92.99 and its two-hundred day moving average price is $85.93.

Insiders Place Their Bets

In other news, EVP Arthur C. Butcher sold 14,010 shares of the company’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $89.27, for a total value of $1,250,672.70. Following the sale, the executive vice president now directly owns 978 shares of the company’s stock, valued at approximately $87,306.06. This represents a 93.47 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP John Bradley Sorenson sold 4,119 shares of the company’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $90.02, for a total transaction of $370,792.38. Following the completion of the sale, the executive vice president now directly owns 35,319 shares in the company, valued at approximately $3,179,416.38. This represents a 10.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 29,989 shares of company stock valued at $2,702,261 in the last ninety days. 0.50% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. Sanford C. Bernstein lifted their price objective on shares of Boston Scientific from $92.00 to $100.00 and gave the stock an “outperform” rating in a research note on Thursday, October 24th. StockNews.com upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a research note on Wednesday. Truist Financial lifted their price objective on shares of Boston Scientific from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, December 18th. Stifel Nicolaus boosted their target price on shares of Boston Scientific from $85.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, October 18th. Finally, BTIG Research boosted their target price on shares of Boston Scientific from $84.00 to $93.00 and gave the company a “buy” rating in a research report on Monday, October 14th. Two investment analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $97.26.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.